Ascentage Pharma Group International (AAPG) Payables (2023 - 2025)

Ascentage Pharma Group International (AAPG) has reported Payables for 3 consecutive years, with $15.0 million the latest figure, recorded in Q4 2025.

• Quarterly Payables rose 17.55% year-over-year to $15.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $15.0 million (up 17.55% YoY) and the FY2025 annual result came in at $14.9 million, up 16.01% from the prior year.
• Payables eased to $15.0 million in Q4 2025 per AAPG's latest filing, from $16.6 million in the prior quarter.
• Over the last five years, Payables for AAPG reached as high as $16.6 million in Q2 2025 and fell as low as $10.1 million in Q4 2023.
• A 3-year average of $13.6 million and a median of $13.9 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2024 — Payables climbed 27.25% — and 2025, when it rose 17.55%.
• Year by year, Payables stood at $10.1 million in 2023, then advanced by 27.25% to $12.8 million in 2024, then gained by 17.55% to $15.0 million in 2025.
• According to Business Quant data, Payables over the past three periods registered $15.0 million, $16.6 million, and $12.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.